|
1. Biologie
|
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
3.1 Tabac
|
|
|
E-cigarette flavorings have dangerous chemicals [STAT]
|
|
|
|
|
|
The
Environmental Health Perspectives, a journal published by the National
Institute of Environmental Health Sciences, says that some companies
hide the presence of the flavoring chemical, known as diacetyl, as well
as other potentially harmful artificial flavorings.
|
|
|
|
|
|
|
E-cigarettes contain flavouring chemical linked to deadly 'popcorn lung' [The Telegraph]
|
|
|
|
|
|
"Since
most of the health concerns about e-cigarettes have focused on
nicotine, there is still much we do not know about e-cigarettes” said
study co-author Dr David Christiani, Professor of Environmental
Genetics. “In addition to containing varying levels of the addictive
substance nicotine, they also contain other cancer-causing chemicals,
such as formaldehyde, and as our study shows, flavouring chemicals that
can cause lung damage.”
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
With SQZ Deal, Roche Finally Dips Its Toes into Cell Therapy [Xconomy]
|
|
|
|
|
|
SQZ
has made a chip that can be used to sort cells, one by one, and insert
material into cells without killing them. Roche and SQZ want to take
antigens from a patient’s tumor, insert them into the patient’s B
cells—all done outside the body—then give the “stuffed” B cells back to
the patient. The theory is that the modified B cells would train the
body’s T cells to hunt down the cancer.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
Threshold Goes Under the Threshold [In the Pipeline]
|
|
|
|
|
|
Threshold’s
idea was not a bad one at all. It just didn’t work, for reasons that
are not clear. A lot of clinical results are not clear – even the good
results aren’t always good for the reasons that people were expecting.
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
|
|
|
|
|
|
|
|
5.8.3 ASH - Divers
|
|
|
|
5.8.4 ASH - CAR T
|
|
|
|
|
|
5.8.5 ASH - Myélome multiple
|
|
|
|
|
|
|
ASH 2015: Novel combination approaches for multiple myeloma [ecancer.tv]
|
|
|
|
|
|
The
panel discuss novel combination approaches to treat multiple myeloma,
the role of monoclonal antibodies both as single agent or in
combination, and side effect management. They cover several data sets
including daratumumab monotherapy in patients with heavily pretreated
relapsed or refractory multiple myloma.
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
ASCO and ACS Issue New Guideline on Breast Cancer Survivorship Care [ASCO]
|
|
|
|
|
|
The
guideline recommendations were developed by a multidisciplinary expert
workgroup, with expertise in primary care, gynecology, surgical
oncology, medical oncology, radiation oncology and nursing. In addition,
a cancer survivor was included to provide a patient perspective. The
workgroup conducted a systematic review of literature published through
April 2015 and identified 237 relevant articles.
|
|
|
|
|
|
|
Organizations issue joint guidelines for breast cancer survivors [Reuters]
|
|
|
|
|
|
The
guidelines issued today by the American Cancer Society and the American
Society of Clinical Oncology (ASCO) provide an updated road map to help
women and their primary care doctors navigate not just surveillance for
new tumors but also a range of mental and physical health problems that
can accompany survivorship.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
|
The Importance of Opt-In [ORCID]
|
|
|
|
|
|
The
Create on Demand process enables the member organization to explicitly
request permissions from a researcher (“opt in”) to read and write to
that individual’s ORCID record. This process also improves the user
experience for researchers with better information flow and fewer clicks
to register.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|